{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:19:55Z","timestamp":1761862795303},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1007\/s11886-008-0052-y","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T07:05:20Z","timestamp":1224054320000},"page":"327-333","source":"Crossref","is-referenced-by-count":5,"title":["Antiplatelet therapy in acute coronary syndromes"],"prefix":"10.1007","volume":"10","author":[{"given":"Colin M.","family":"Barker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,10,16]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","volume":"113","author":"A.L. Frelinger","year":"2006","unstructured":"Frelinger AL, Furman MI, Linden MD, et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113:2888\u20132896.","journal-title":"Circulation"},{"key":"52_CR2","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","volume":"313","author":"J.A. Cairns","year":"1985","unstructured":"Cairns JA, Gent M, Singer J, et al.: Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985, 313:1369\u20131375.","journal-title":"N Engl J Med"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/0735-1097(91)90489-V","volume":"18","author":"L.C. Wallentin","year":"1991","unstructured":"Wallentin LC: Aspirin (75 mg\/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991, 18:1587\u20131593.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR4","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. The Antithrombotic Trialists\u2019 Collaboration [no authors listed]. BMJ 2002, 324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1161\/CIRCULATIONAHA.107.729558","volume":"117","author":"J.S. Berger","year":"2008","unstructured":"Berger JS, Stebbins A, Granger CB, et al.: Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy. Circulation 2008, 117:192\u2013199.","journal-title":"Circulation"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2004.01063.x","volume":"3","author":"B. Aleil","year":"2005","unstructured":"Aleil B, Ravanat C, Cazenave JP, et al.: Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005, 3:85\u201392.","journal-title":"J Thromb Haemost"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1172\/JCI12242","volume":"107","author":"C.J. Foster","year":"2001","unstructured":"Foster CJ, Prosser DM, Agans JM, et al.: Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001, 107:1591\u20131598.","journal-title":"J Clin Invest"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"M.B. Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998, 339:1665\u20131671.","journal-title":"N Engl J Med"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0140-6736(05)61186-5","volume":"349","author":"A. Haushofer","year":"1997","unstructured":"Haushofer A, Halbmayer WM, Prachar H: Neutropenia with ticlopidine plus aspirin. Lancet 1997, 349:474\u2013475.","journal-title":"Lancet"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jacc.2007.04.092","volume":"50","author":"G. Campo","year":"2007","unstructured":"Campo G, Valgimigli M, Gemmati D, et al.: Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism?: evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 2007, 50:1132\u20131137.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.jacc.2007.08.016","volume":"50","author":"K.F. Tiehl von","year":"2007","unstructured":"von Tiehl KF, Price MJ, Valencia R, et al.: Clopidogrel desensitization after drug-eluting stent placement. J Am Coll Cardiol 2007, 50:2039\u20132043.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","volume":"49","author":"D.J. Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al.: Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49:1505\u20131516.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S. Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494\u2013502.","journal-title":"N Engl J Med"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"S.R. Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527\u2013533.","journal-title":"Lancet"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"M.S. Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM, et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179\u20131189","journal-title":"N Engl J Med"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.294.10.1224","volume":"294","author":"M.S. Sabatine","year":"2005","unstructured":"Sabatine MS, Cannon C, Gibson CM, et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005, 294:1224\u20131232.","journal-title":"JAMA"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.amjcard.2006.03.054","volume":"98","author":"M.J. Price","year":"2006","unstructured":"Price MJ, Coleman JL, Steinhubl SR, et al.: Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 2006, 98:681\u2013684.","journal-title":"Am J Cardiol"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jacc.2004.09.067","volume":"45","author":"V.L. Serebruany","year":"2005","unstructured":"Serebruany VL, Steinhubl SR, Berger PB, et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246\u2013251.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","volume":"111","author":"W. Hochholzer","year":"2005","unstructured":"Hochholzer W, Trenk D, Frundi D, et al.: Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111:2560\u20132564.","journal-title":"Circulation"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1538-7836.2005.01751.x","volume":"4","author":"T. Cuisset","year":"2006","unstructured":"Cuisset T, Frere C, Quilici J, et al.: High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006, 4:542\u2013549.","journal-title":"J Thromb Haemost"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","volume":"49","author":"P. Buonamici","year":"2007","unstructured":"Buonamici P, Marcucci R, Migliorini A, et al.: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312\u20132317.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR22","doi-asserted-by":"crossref","unstructured":"Price MJ, Endemann S, Gallapudi RR, et al.: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008 Feb 10 (Epub ahead of print).","DOI":"10.1093\/eurheartj\/ehn046"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1161\/CIRCULATIONAHA.105.559088","volume":"112","author":"N. Beckerath von","year":"2005","unstructured":"von Beckerath N, Taubert D, Pogatsa-Murray G, et al.: Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005, 112:2946\u20132950.","journal-title":"Circulation"},{"key":"52_CR24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1161\/CIRCULATIONAHA.106.667741","volume":"115","author":"D.J. Angiolillo","year":"2007","unstructured":"Angiolillo DJ, Shoemaker SB, Desai B, et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study. Circulation 2007, 115:708\u2013716.","journal-title":"Circulation"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.athoracsur.2005.03.074","volume":"80","author":"J.Y. Leong","year":"2005","unstructured":"Leong JY, Baker RA, Shah PJ, et al.: Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 2005, 80:928\u2013933.","journal-title":"Ann Thorac Surg"},{"key":"52_CR26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/eurheartj\/ehi074","volume":"26","author":"E.I. Kapetanakis","year":"2005","unstructured":"Kapetanakis EI, Medlam DA, Boyce SW, et al.: Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist\u2019s panacea or the surgeon\u2019s headache? Eur Heart J 2005, 26:576\u2013583.","journal-title":"Eur Heart J"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1592\/phco.28.2.151","volume":"2","author":"M.G. Reichert","year":"2008","unstructured":"Reichert MG, Robinson AH, Travis JA, et al.: Effects of a waiting period after clopidogrel treatment before performing coronary artery bypass grafting. Pharmacotherapy 2008, 2:151\u2013156.","journal-title":"Pharmacotherapy"},{"key":"52_CR28","doi-asserted-by":"crossref","unstructured":"ACC\/AHA 2007 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction\u2014Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines [no authors listed]. J Am Coll Cardiol 2007, 50:652\u2013726.","DOI":"10.1016\/j.jacc.2007.02.028"},{"key":"52_CR29","doi-asserted-by":"crossref","unstructured":"Price MJ: Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. Am J Cardiol 2008 (in press).","DOI":"10.1016\/j.amjcard.2008.02.109"},{"key":"52_CR30","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1093\/eurheartj\/ehi877","volume":"27","author":"T. Jernberg","year":"2006","unstructured":"Jernberg T, Payne CD, Winters KJ, et al.: Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006, 27:1166\u20131173.","journal-title":"Eur Heart J"},{"key":"52_CR31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/FJC.0b013e3181492209","volume":"50","author":"C.D. Payne","year":"2007","unstructured":"Payne CD, Li YG, Small DS, et al.: Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007, 50:555\u2013562.","journal-title":"J Cardiovasc Pharmacol"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"S.D. Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL, et al.: Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasurgrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 Trial. Circulation 2007, 116:2923\u20132932.","journal-title":"Circulation"},{"key":"52_CR33","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"S.D. Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al.: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001\u20132015.","journal-title":"N Engl J Med"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","volume":"17","author":"B. Springthorpe","year":"2007","unstructured":"Springthorpe B, Bailey A, Barton P, et al.: From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg Med Chem Lett 2007, 17:6013\u20136018.","journal-title":"Bioorg Med Chem Lett"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","volume":"27","author":"S. Husted","year":"2006","unstructured":"Husted S, Emanuelsson H, Heptinstall S, et al.: Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006, 27:1038\u20131047.","journal-title":"Eur Heart J"},{"key":"52_CR36","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"R.F. Storey","year":"2007","unstructured":"Storey RF, Husted S, Harrington RA, et al.: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Cardiol Coll 2007, 50:1852\u20131856.","journal-title":"J Am Cardiol Coll"},{"key":"52_CR37","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","volume":"50","author":"C.P. Cannon","year":"2007","unstructured":"Cannon CP, Husted S, Harrington RA, et al.: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DIS-PERSE-2 Trial. J Am Cardiol Coll 2007, 50:1844\u20131851.","journal-title":"J Am Cardiol Coll"},{"key":"52_CR38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","volume":"85","author":"R.F. Storey","year":"2001","unstructured":"Storey RF, Oldroyd KG, Wilcox RG: Open multicentre study of the P 2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb Haemost 2001, 85:401\u2013407.","journal-title":"Thromb Haemost"},{"key":"52_CR39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"S.R. Steinhubl","year":"2008","unstructured":"Steinhubl SR, Oh JJ, Oestreich JH, et al.: Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 2008, 121:527\u2013534.","journal-title":"Thromb Res"},{"key":"52_CR40","first-page":"689.e1","volume":"151","author":"A.B. Greenbaum","year":"2006","unstructured":"Greenbaum AB, Grines CL, Bittl JA, et al.: Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am J Cardiol 2006, 151:689.e1\u2013689.e10.","journal-title":"Am J Cardiol"},{"key":"52_CR41","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/01.ATV.0000053387.06709.32","volume":"23","author":"A.T. Nurden","year":"2003","unstructured":"Nurden AT, Nurden P: Advantages of fast-acting ADP receptor blockade in ischemic heart disease. Arterioscler Thromb Vasc Biol 2003, 23:158\u2013159.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"52_CR42","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/blood-2004-04-1257","volume":"104","author":"S.J. Shattil","year":"2004","unstructured":"Shattil SJ, Newman PJ: Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood 2004, 104:1606\u20131615.","journal-title":"Blood"},{"key":"52_CR43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","volume":"359","author":"E. Boersma","year":"2002","unstructured":"Boersma E, Harrington RA, Moliterno DJ, et al.: Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189\u2013198.","journal-title":"Lancet"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1161\/01.CIR.103.24.2891","volume":"103","author":"L.K. Newby","year":"2001","unstructured":"Newby LK, Ohman EM, Christenson RH, et al.: Benefit of glycoprotein IIb\/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status: the PARAGON-B Troponin T Substudy. Circulation 2001, 103:2891\u20132896.","journal-title":"Circulation"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1001\/jama.295.13.joc60034","volume":"295","author":"A. Kastrati","year":"2006","unstructured":"Kastrati A, Mehilli J, Neumann FJ, et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. The ISAR-REACT 2 Randomized Trial. JAMA 2006, 295:1531\u20131538.","journal-title":"JAMA"},{"key":"52_CR46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa031859","volume":"350","author":"A. Kastrati","year":"2004","unstructured":"Kastrati A, Mehilli J, Sch\u00fchlen H, et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004, 350:232\u2013238.","journal-title":"N Engl J Med"},{"key":"52_CR47","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.298.21.2497","volume":"298","author":"G.W. Stone","year":"2007","unstructured":"Stone GW, Ware JH, Bertrand ME: Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management. One-year results from the ACUITY trial. JAMA 2007, 298:2497\u20132506.","journal-title":"JAMA"},{"key":"52_CR48","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.jacc.2005.11.012","volume":"47","author":"L. Bolognese","year":"2006","unstructured":"Bolognese L, Falsini G, Liistro F, et al.: Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006, 47:522\u2013528.","journal-title":"J Am Coll Cardiol"},{"key":"52_CR49","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/jama.292.13.1555","volume":"292","author":"S.V. Rao","year":"2004","unstructured":"Rao SV, Jollis JG, Harrington RA, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004, 292:1555\u20131562.","journal-title":"JAMA"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-008-0052-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-008-0052-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-008-0052-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:56:09Z","timestamp":1559433369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-008-0052-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s11886-008-0052-y","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7]]}}}